Markets Gone Wild

Ionis Pharmaceuticals: A New Chapter as a Commercial-Stage Biotech Company Carlsbad, CA – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) recently reported its financial results for the fourth quarter and full year ended December 31, 2024. This report marks a significant milestone for the biotechnology company as it has launched its first independent medicine, TRYNGOLZA, for the…

Exciting Times in the World of Quantum Computing The Breakthrough Announcement from Google Picture this: it’s early December, and Alphabet’s Google drops a bombshell in the world of technology. A breakthrough in quantum computing that has the potential to shake things up in a major way. The Willow quantum chip is the star of the…

Welcome to the Alkami Technology, Inc. Financial Results Announcement Get Ready for Some Exciting News! Mark your calendars! Alkami Technology, Inc. is gearing up to share their financial results for the fourth quarter of 2024. The highly anticipated announcement is scheduled for Thursday, February 27, 2025, right after the market closes. Make sure to tune…

Unlocking the Power of Accesswire: A Comprehensive Guide to Maximizing Your Online Presence Introduction In today’s digital age, having a strong online presence is crucial for individuals and businesses alike. One platform that is gaining popularity for its ability to amplify online visibility is Accesswire. If you are looking to enhance your online presence and…

Dream Office REIT Announces February 2025 Distribution Overview TORONTO–(BUSINESS WIRE)–DREAM OFFICE REIT (TSX: D.UN) (“Dream Office” or the “Trust”) today announced its February 2025 monthly distribution of 8.333 cents ($1.00 annualized) per REIT Unit, Series A (“REIT A Units”). The February distribution will be payable on March 14, 2025 to unitholders of record as at…

Regeneron Pharmaceuticals Faces Class Action Lawsuit NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP has announced that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). The Company, a leading biotechnology firm, is facing legal scrutiny from investors due to alleged misconduct. Investors Should Take Note If…